QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ARVN

QT55Arvinas, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
7.67
+0.00%
OverviewShort InterestFilings
ARVNQT55Arvinas, Inc.·NASDAQ
OverviewShort InterestFilings
7.67+0.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.26
Insider Own15.20%
Shs Outstand64.52M
Perf Week8.18%
Market Cap494.88MForward P/E-EPS next Y-3.52Insider Trans-0.15%Shs Float-Perf Month-10.29%
Enterprise Value-PEG-EPS next Q-0.24Inst Own-Short Float-Perf Quarter-31.33%
Income-P/S-EPS this Y12.18%Inst Trans-Short Ratio-Perf Half Y-35.55%
Sales-P/B-EPS next Y-22.78%ROA-Short Interest-Perf YTD-35.33%
Book/sh6.00P/C-EPS next 5Y-ROE-52W High14.51 -47.14%Perf Year2.54%
Cash/sh9.53P/FCF-EPS past 3/5Y-ROIC-52W Low6.06 26.57%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y26.15% 58.85%Gross Margin-Volatility4.07% 3.34%Perf 5Y-
Dividend TTM-EV/Sales-EPS Y/Y TTM-19.86%Oper. Margin-ATR (14)0.45Perf 10Y-
Dividend Ex-Date-Quick Ratio-Sales Y/Y TTM-65.78%Profit Margin-RSI (14)38.85Recom2.40
Dividend Gr. 3/5Y-Current Ratio-EPS Q/Q-178.95%SMA20-3.81%Beta1.06Target Price14.75
Payout-Debt/Eq-Sales Q/Q-91.53%SMA50-17.64%Rel Volume1.17Prev Close7.67
Employees430LT Debt/Eq0.02EarningsAug 05SMA200-28.07%Avg Volume818.64KPrice7.67
IPO DateSep 27, 2018Option/ShortYes / YesEPS/Sales Surpr.5.26% -5.88%Net Debt/EBITDA-Volume957,393Change0.00%
Analyst Ratings
DateActionAnalystRatingTarget
May-13-26ReiteratedBarclaysOverweight$18 → $20
May-13-26ReiteratedBTIGBuy$14 → $18
Mar-18-26ReiteratedTruist Financial$11 → $10
Jan-06-26UpgradeCitigroupNeutral → Buy
Dec-17-25ReiteratedBarclaysOverweight$16 → $18
Oct-30-25ReiteratedBTIGBuy$10 → $14
Oct-15-25DowngradeGoldman SachsNeutral → Sell$6.00
Oct-07-25ReiteratedPiper SandlerOverweight$14 → $16
Sep-18-25ReiteratedStephens$16 → $14
Sep-18-25ReiteratedBTIGBuy$16 → $10
Latest News
Jun-16-26
Jun-16-2604:04PM
Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The AgreementBenzinga
Jun-11-26
Jun-11-2606:49PM
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform PotentialSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue90263263
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A250
Gross Profit87257263
Selling, General and Administrative Excl. Other8689165
Research and Development255283348
Other Operating Expense-401
Operating Income-250-115-250
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-28-34-52
Net Income Before Taxes-220-80-198
Income Taxes001
Consolidated Net Income-221-81-199
Net Income From Continuing Operations-221-81-199
Net Income-221-81-199
EPS (Recurring)-3.26-1.28-2.77
EPS (Basic, Before Extraordinaries)-3.26-1.28-2.77
EPS (Diluted)-3.26-1.28-2.77
EBITDA-216-75-192
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio5.452.93—
Gross Margin96.6797.72100.00
Operating Margin-277.78-43.73-95.06
Net Margin-245.56-30.80-75.67
Shares Outstanding646572
Market Capitalization491771—
Operating Lease Expense
———
Insider Trading Volume
$8.16$7.31$6.46$5.60$4.75● Close Price0.00K207.34K414.69K622.03K829.38KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Teel RandyPresident and CEOMay 21 '26Sale9.042,20919,962285,009May 22 12:00 AM
Berkowitz NoahChief Medical OfficerMay 11 '26Sale9.9411,108110,385191,395May 13 12:00 AM
Teel RandyPresident and CEOMay 11 '26Sale9.949,65795,965287,218May 13 12:00 AM
Saik AndrewChief Financial OfficerMay 11 '26Sale9.9411,139110,693193,128May 13 12:00 AM
Cacace Angela MChief Scientific OfficerMay 11 '26Sale9.949,65795,965182,966May 13 12:00 AM
Loomis David KVP, Chief Accounting OfficerMay 11 '26Sale9.941,91919,07040,193May 13 12:00 AM
Berkowitz NoahChief Medical OfficerMar 18 '26Sale11.106,43571,431202,503Mar 19 12:00 AM
Morrison BriggsDirectorMar 06 '26Buy13.4020,000268,07096,021Mar 09 12:00 AM
Houston John GDirectorFeb 27 '26Sale13.2135,297466,1531,122,183Mar 02 12:00 AM
Teel RandyPresident and CEOFeb 23 '26Sale12.164,78658,198149,696Feb 25 12:00 AM
Loomis David KChief Accounting OfficerFeb 23 '26Sale12.161,10813,47329,692Feb 25 12:00 AM
Cacace Angela MChief Scientific OfficerFeb 23 '26Sale12.163,60943,885147,623Feb 25 12:00 AM
Teel RandyPresident and CEOFeb 13 '26Sale11.894,40352,352154,482Feb 18 12:00 AM
Saik AndrewChief Financial OfficerFeb 13 '26Sale11.895,13461,043159,267Feb 18 12:00 AM
Cacace Angela MChief Scientific OfficerFeb 13 '26Sale11.894,59254,599151,232Feb 18 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR